158. 結節性硬化症 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 112 / 薬物数 : 71 - (DrugBank : 19) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 118
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
AED
Peking Union Medical College Hospital
2017 Phase 2 NCT03356769 China;
Afinitor
Cardiff University
2012 Phase 2 EUCTR2011-004854-25-GB United Kingdom;
Novartis Pharma Services AG
- Phase 3 EUCTR2010-022583-13-FR Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain;
- Phase 3 EUCTR2008-002113-48-DE Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
Afinitor 5mg Tablets
Novartis Pharma Services AG
2009 Phase 3 EUCTR2008-002113-48-GB Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
Antiepileptic drug (1 to 3 only)
Novartis Pharmaceuticals
2013 Phase 3 NCT01713946 Argentina;Australia;Belgium;Canada;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Aspirin
Peking Union Medical College Hospital
2017 Phase 2 NCT03356769 China;
Basimglurant
Noema Pharma AG
2021 Phase 2 NCT05059327 -
Bumetanide
UMC Utrecht
2017 Phase 2 EUCTR2016-002408-13-NL Netherlands;
CBD - Oral Solution, is known as Epidyolex 100 mg/ml oral solution,
GW Research Ltd.
- Phase 3 EUCTR2015-002154-12-PL Australia;Netherlands;Poland;Spain;United Kingdom;United States;
CBD-Oral Solution, is known as Epidiolex, and is the approved name in the USA.
GW Research Ltd.
2017 Phase 3 EUCTR2015-002154-12-NL Australia;Netherlands;Poland;Spain;United Kingdom;United States;
Cannabidiol
GW Research Ltd
2021 Phase 4 NCT05044819 United States;
Cannabidiol (CBD)
GW Research Ltd
- Phase 3 EUCTR2020-002132-67-Outside-EU/EEA United States;
GW Research Ltd.
2017 Phase 3 EUCTR2015-002154-12-NL Australia;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002154-12-ES Australia;France;Netherlands;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2015-002154-12-PL Australia;Netherlands;Poland;Spain;United Kingdom;United States;
Cannabidiol Oral Solution, is known as Epidyolex 100 mg/mL oral solution and is the approved name in the EU. Epidiolex (cannabidiol) oral solution is the approved name in the US.
GW Research Ltd
- Phase 3 EUCTR2020-002132-67-Outside-EU/EEA United States;
Certican 1 mg tablets
Novartis Pharma Services AG
2011 - EUCTR2007-006997-27-BE Belgium;Germany;Italy;Netherlands;United Kingdom;
Doxycycline
University of Nottingham
2009 Phase 4 NCT00989742 United Kingdom;
Everolimus
Cardiff University
2012 Phase 2 EUCTR2011-004854-25-GB United Kingdom;
Children's Hospital Medical Center, Cincinnati
2010 Phase 1/Phase 2 NCT01070316 United States;
2007 Phase 1/Phase 2 NCT00411619 United States;
Dana-Farber Cancer Institute
2014 Phase 2 NCT02201212 United States;
Department of Pharmacy, Peking University First Hospita
2020 Phase 4 ChiCTR2000039523 China;
Department of Urology, Keio University School of Medicine
2013 - JPRN-UMIN000011559 Japan;
Erasmus Medical Center
2012 Phase 2/Phase 3 NCT01730209 Netherlands;
General Hospital of PLA
2016 - ChiCTR-OPN-16008236 China;
Hospices Civils de Lyon
2020 Phase 2/Phase 3 NCT02860494 France;
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
2013 Phase 2 NCT01929642 United States;
NOVARTIS FARMA
2011 - EUCTR2010-022583-13-IT Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
2009 - EUCTR2008-002113-48-IT France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2007-006997-27-IT Belgium;Germany;Italy;Netherlands;United Kingdom;
NYU Langone Health
2014 Phase 2 NCT02451696 United States;
Novartis Pharma Services AG
2011 - EUCTR2007-006997-27-BE Belgium;Germany;Italy;Netherlands;United Kingdom;
2010 - EUCTR2007-006997-27-NL Australia;Belgium;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;
2010 - EUCTR2007-006997-27-DE Belgium;Germany;Italy;Netherlands;United Kingdom;
2009 Phase 3 EUCTR2008-002113-48-GB Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2009 Phase 3 EUCTR2007-006997-27-GB Belgium;Germany;Italy;Netherlands;United Kingdom;
Novartis Pharmaceuticals
2022 Phase 4 NCT05252585 -
2018 Phase 4 NCT03525834 China;
2017 Phase 3 NCT02962414 Australia;Belgium;Canada;Colombia;France;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2009 Phase 3 NCT00789828 Australia;Belgium;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Everolimus (RAD001)
Cardiff University
2012 Phase 2 NCT01954693 United Kingdom;
Children's Hospital Medical Center, Cincinnati
2008 Phase 1/Phase 2 NCT00792766 United States;
Novartis Pharmaceuticals
2009 Phase 3 NCT00790400 Canada;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Everolimus 2mg dispersible tablet
Novartis Pharma Services AG
2013 Phase 3 EUCTR2011-000860-90-DE Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Everolimus Oral Product
University of Pennsylvania
2014 Phase 1/Phase 2 NCT02061397 United States;
GWP42003-P
GW Research Ltd
2021 Phase 3 NCT04485104 United States;
2016 Phase 3 NCT02544763 Australia;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 NCT02544750 United States;
- Phase 3 EUCTR2020-002132-67-Outside-EU/EEA United States;
GW Research Ltd.
2017 Phase 3 EUCTR2015-002154-12-NL Australia;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002154-12-ES Australia;France;Netherlands;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2015-002154-12-PL Australia;Netherlands;Poland;Spain;United Kingdom;United States;
Ganaxolone
Marinus Pharmaceuticals
2020 Phase 2 NCT04285346 United States;
Gold
An Zhen Hospital affiliated to Capital Medical University, Beijing
Beijing Key Laboratory of Fetal Heart Diseases and Maternal-Fetal Medicine
L04AA18
Erasmus MC - Department of Neurology
2012 - EUCTR2010-019519-39-NL Netherlands;
Metformin (generic)
University Hospitals Bristol NHS Foundation Trust
2012 Phase 4 EUCTR2011-001319-30-GB United Kingdom;
Metformin hydrochloride
University Hospitals Bristol NHS Foundation Trust
2012 Phase 4 EUCTR2011-001319-30-GB United Kingdom;
NPC-12G gel
Nobelpharma
2015 Phase 3 NCT02635789 Japan;
2015 Phase 3 NCT02634931 Japan;
Open label RAD001 (only used for post-extension phase)
Novartis Pharmaceuticals
2013 Phase 3 NCT01713946 Argentina;Australia;Belgium;Canada;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Petrolatum
Department of DermatologyGraduate School of Medicine, Osaka University
2009 Phase 2,3 JPRN-UMIN000002844 Japan;
Propranolol
University Hospital, Bordeaux
2015 Phase 2 NCT02104011 France;
RAD001
Cardiff University
2012 Phase 2 EUCTR2011-004854-25-GB United Kingdom;
Children's Hospital Medical Center, Cincinnati
2005 Phase 1/Phase 2 NCT00457964 United States;
Mustafa Sahin
2011 Phase 2 NCT01289912 United States;
NOVARTIS FARMA
2013 Phase 3 EUCTR2011-000860-90-IT Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2011 - EUCTR2010-022583-13-IT Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
2009 - EUCTR2008-002113-48-IT France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2007-006997-27-IT Belgium;Germany;Italy;Netherlands;United Kingdom;
Novartis Farmacéutica S.A
2017 Phase 3 EUCTR2016-002977-37-ES Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Novartis Farmacéutica, S.A
2013 - EUCTR2012-005397-63-ES Spain;
Novartis Farmacéutica, S.A.
2013 Phase 3 EUCTR2011-000860-90-ES Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Novartis Pharma AG
2017 Phase 3 EUCTR2016-002977-37-HU Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002977-37-GB Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002977-37-FR Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002977-37-BE Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2016-002977-37-PL Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Novartis Pharma Services AG
2014 Phase 3;Phase 4 EUCTR2013-003795-13-BE Belgium;Canada;Poland;Russian Federation;United States;
2014 Phase 3 EUCTR2011-000860-90-IE Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-NL Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-HU Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-GR Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-GB Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-DK Argentina;Belgium;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Spain;Taiwan;Turkey;United Kingdom;
2013 Phase 3 EUCTR2011-000860-90-DE Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-BE Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022583-13-CZ Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain;
2011 Phase 3 EUCTR2010-022583-13-BE Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
2011 - EUCTR2010-022583-13-HU Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
2011 - EUCTR2010-022583-13-GR Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
2011 - EUCTR2007-006997-27-BE Belgium;Germany;Italy;Netherlands;United Kingdom;
2010 - EUCTR2008-002113-48-NL France;Germany;Italy;Netherlands;Spain;United Kingdom;
2010 - EUCTR2007-006997-27-NL Australia;Belgium;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;
2010 - EUCTR2007-006997-27-DE Belgium;Germany;Italy;Netherlands;United Kingdom;
2009 Phase 3 EUCTR2008-002113-48-GB Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002113-48-FR France;Germany;Italy;Netherlands;Spain;United Kingdom;
- Phase 3 EUCTR2013-003795-13-PL Belgium;Canada;Poland;Russian Federation;United States;
- Phase 3 EUCTR2010-022583-13-FR Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain;
- Phase 3 EUCTR2008-002113-48-DE Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
RAD001 2,
Novartis Pharma Services AG
- - EUCTR2010-022583-13-DE Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
RAD001 round tablets
Novartis Pharma Services AG
2009 Phase 3 EUCTR2007-006997-27-GB Belgium;Germany;Italy;Netherlands;United Kingdom;
RAPAMUNE 1 mg/ml oral solution
The Children's Memorial Health Institute
- Phase 2;Phase 3 EUCTR2020-003231-19-PL Poland;
Rapamune
Erasmus MC
2011 - EUCTR2010-022655-29-NL Netherlands;
FUNDACIÓ PUIGVERT
2008 - EUCTR2007-005978-30-ES Spain;
Le Bonheur Children's Hospital
2013 Phase 1 NCT01853423 United States;
Rapamune 1 mg/ml solución oral
Fundación Investigación Hospital Ramón y Cajal
2012 - EUCTR2011-006308-12-ES Spain;
Rapamycin
Chinese PLA General Hospital
2015 - ChiCTR-OOB-15006535 China;
Department of Dermatology Graduate School of Medicine, Osaka University
2014 Phase 2,3 JPRN-UMIN000015114 Japan;
2011 Phase 2,3 JPRN-UMIN000006108 Japan;
Department of DermatologyGraduate School of Medicine, Osaka University
2009 Phase 2,3 JPRN-UMIN000002844 Japan;
Dermatology Specialties Limited Partnership
2019 Phase 2/Phase 3 NCT03826628 Australia;Czechia;Hungary;New Zealand;Serbia;Slovakia;Spain;Taiwan;United Kingdom;United States;
The University of Texas Health Science Center, Houston
2012 Phase 2 NCT01526356 Australia;United States;
Rapamycin cream, topical, , w/w
DSLP
2019 Phase 2;Phase 3 EUCTR2019-000752-34-SK Australia;Hungary;New Zealand;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000752-34-HU Australia;Hungary;New Zealand;Slovakia;Spain;United Kingdom;United States;
Dermatology Specialities Limited Partnership (DSLP)
- Phase 2;Phase 3 EUCTR2019-000752-34-CZ Australia;Czech Republic;Hungary;New Zealand;Serbia;Slovakia;Spain;United States;
Rapamycin, sirolimus
Children's Hospital Medical Center, Cincinnati
2002 Phase 2 NCT00457808 United States;
Rapamycin-calcitriol combination
National Taiwan University Hospital
2013 Phase 3 NCT03140449 -
SABRIL 500 mg, granules for oral solution
The Children's Memorial Health Institute
- Phase 2;Phase 3 EUCTR2020-003231-19-PL Poland;
SOC
GW Research Ltd
2021 Phase 3 NCT04485104 United States;
Simvastatin
University of Pennsylvania
2014 Phase 1/Phase 2 NCT02061397 United States;
Sirolimus
Aucta Pharmaceuticals, Inc
2017 Phase 2 NCT03363763 China;United States;
Cardiff University
2005 Phase 2 NCT00490789 United Kingdom;
Darcy Krueger
2021 Phase 2 NCT05104983 United States;
Department of DermatologyGraduate School of Medicine, Osaka University
2013 Phase 1,2 JPRN-UMIN000012420 Japan;
FUNDACIÓ PUIGVERT
2008 - EUCTR2007-005978-30-ES Spain;
Fundacio Puigvert
2008 Phase 4 NCT01217125 -
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
2013 Phase 2 NCT01929642 United States;
West China Hospital, Sichuan University
2020 - ChiCTR2000031984 China;
Sirolimus Oral Product
University of Pennsylvania
2014 Phase 1/Phase 2 NCT02061397 United States;
Skincerity plus sirolimus/rapamycin
The University of Texas Health Science Center, Houston
2009 Phase 1 NCT01031901 United States;
Skinercity plus sirolimus/rapamycin
The University of Texas Health Science Center, Houston
2009 Phase 1 NCT01031901 United States;
TAVT-18 (sirolimus)
Children's Hospital Medical Center, Cincinnati
2020 Phase 1/Phase 2 NCT04595513 United States;
Tacrolimus
Department of DermatologyGraduate School of Medicine, Osaka University
2009 Phase 2,3 JPRN-UMIN000002844 Japan;
Turmeric
NYU Langone Health
2018 - NCT03254680 United States;
Vigabatrin
Martina Bebin
2016 Phase 2 NCT02849457 United States;
University of Pennsylvania
2010 Phase 4 NCT01266291 United States;
Vigabatrin (Sabril)
The Children's Memorial Health Institute
2014 - EUCTR2013-005528-40-NL Belgium;Netherlands;
Vigabatrin (sabril)
Vrije Universiteit Brussel
2014 - EUCTR2013-005528-40-BE Belgium;Netherlands;
Votubia
Erasmus MC - Department of Neurology
2012 - EUCTR2010-019519-39-NL Netherlands;
NOVARTIS PHARMA AG
2019 Phase 3 EUCTR2016-002977-37-IT Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Novartis Farmacéutica S.A
2017 Phase 3 EUCTR2016-002977-37-ES Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Novartis Farmacéutica, S.A
2013 - EUCTR2012-005397-63-ES Spain;
Novartis Pharma AG
2017 Phase 3 EUCTR2016-002977-37-HU Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002977-37-GB Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002977-37-FR Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002977-37-BE Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2016-002977-37-PL Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Novartis Pharma Services AG
2014 Phase 3;Phase 4 EUCTR2013-003795-13-BE Belgium;Canada;Poland;Russian Federation;United States;
2014 Phase 3 EUCTR2011-000860-90-IE Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-NL Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-HU Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-GB Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-DK Argentina;Belgium;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Spain;Taiwan;Turkey;United Kingdom;
2013 Phase 3 EUCTR2011-000860-90-BE Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022583-13-BE Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
- Phase 3 EUCTR2013-003795-13-PL Belgium;Canada;Poland;Russian Federation;United States;
Peking Union Medical College Hospital
2017 Phase 2 NCT03356769 China;
Afinitor
Cardiff University
2012 Phase 2 EUCTR2011-004854-25-GB United Kingdom;
Novartis Pharma Services AG
- Phase 3 EUCTR2010-022583-13-FR Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain;
- Phase 3 EUCTR2008-002113-48-DE Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
Afinitor 5mg Tablets
Novartis Pharma Services AG
2009 Phase 3 EUCTR2008-002113-48-GB Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
Antiepileptic drug (1 to 3 only)
Novartis Pharmaceuticals
2013 Phase 3 NCT01713946 Argentina;Australia;Belgium;Canada;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Aspirin
Peking Union Medical College Hospital
2017 Phase 2 NCT03356769 China;
Basimglurant
Noema Pharma AG
2021 Phase 2 NCT05059327 -
Bumetanide
UMC Utrecht
2017 Phase 2 EUCTR2016-002408-13-NL Netherlands;
CBD - Oral Solution, is known as Epidyolex 100 mg/ml oral solution,
GW Research Ltd.
- Phase 3 EUCTR2015-002154-12-PL Australia;Netherlands;Poland;Spain;United Kingdom;United States;
CBD-Oral Solution, is known as Epidiolex, and is the approved name in the USA.
GW Research Ltd.
2017 Phase 3 EUCTR2015-002154-12-NL Australia;Netherlands;Poland;Spain;United Kingdom;United States;
Cannabidiol
GW Research Ltd
2021 Phase 4 NCT05044819 United States;
Cannabidiol (CBD)
GW Research Ltd
- Phase 3 EUCTR2020-002132-67-Outside-EU/EEA United States;
GW Research Ltd.
2017 Phase 3 EUCTR2015-002154-12-NL Australia;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002154-12-ES Australia;France;Netherlands;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2015-002154-12-PL Australia;Netherlands;Poland;Spain;United Kingdom;United States;
Cannabidiol Oral Solution, is known as Epidyolex 100 mg/mL oral solution and is the approved name in the EU. Epidiolex (cannabidiol) oral solution is the approved name in the US.
GW Research Ltd
- Phase 3 EUCTR2020-002132-67-Outside-EU/EEA United States;
Certican 1 mg tablets
Novartis Pharma Services AG
2011 - EUCTR2007-006997-27-BE Belgium;Germany;Italy;Netherlands;United Kingdom;
Doxycycline
University of Nottingham
2009 Phase 4 NCT00989742 United Kingdom;
Everolimus
Cardiff University
2012 Phase 2 EUCTR2011-004854-25-GB United Kingdom;
Children's Hospital Medical Center, Cincinnati
2010 Phase 1/Phase 2 NCT01070316 United States;
2007 Phase 1/Phase 2 NCT00411619 United States;
Dana-Farber Cancer Institute
2014 Phase 2 NCT02201212 United States;
Department of Pharmacy, Peking University First Hospita
2020 Phase 4 ChiCTR2000039523 China;
Department of Urology, Keio University School of Medicine
2013 - JPRN-UMIN000011559 Japan;
Erasmus Medical Center
2012 Phase 2/Phase 3 NCT01730209 Netherlands;
General Hospital of PLA
2016 - ChiCTR-OPN-16008236 China;
Hospices Civils de Lyon
2020 Phase 2/Phase 3 NCT02860494 France;
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
2013 Phase 2 NCT01929642 United States;
NOVARTIS FARMA
2011 - EUCTR2010-022583-13-IT Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
2009 - EUCTR2008-002113-48-IT France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2007-006997-27-IT Belgium;Germany;Italy;Netherlands;United Kingdom;
NYU Langone Health
2014 Phase 2 NCT02451696 United States;
Novartis Pharma Services AG
2011 - EUCTR2007-006997-27-BE Belgium;Germany;Italy;Netherlands;United Kingdom;
2010 - EUCTR2007-006997-27-NL Australia;Belgium;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;
2010 - EUCTR2007-006997-27-DE Belgium;Germany;Italy;Netherlands;United Kingdom;
2009 Phase 3 EUCTR2008-002113-48-GB Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2009 Phase 3 EUCTR2007-006997-27-GB Belgium;Germany;Italy;Netherlands;United Kingdom;
Novartis Pharmaceuticals
2022 Phase 4 NCT05252585 -
2018 Phase 4 NCT03525834 China;
2017 Phase 3 NCT02962414 Australia;Belgium;Canada;Colombia;France;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2009 Phase 3 NCT00789828 Australia;Belgium;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Everolimus (RAD001)
Cardiff University
2012 Phase 2 NCT01954693 United Kingdom;
Children's Hospital Medical Center, Cincinnati
2008 Phase 1/Phase 2 NCT00792766 United States;
Novartis Pharmaceuticals
2009 Phase 3 NCT00790400 Canada;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Everolimus 2mg dispersible tablet
Novartis Pharma Services AG
2013 Phase 3 EUCTR2011-000860-90-DE Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Everolimus Oral Product
University of Pennsylvania
2014 Phase 1/Phase 2 NCT02061397 United States;
GWP42003-P
GW Research Ltd
2021 Phase 3 NCT04485104 United States;
2016 Phase 3 NCT02544763 Australia;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 NCT02544750 United States;
- Phase 3 EUCTR2020-002132-67-Outside-EU/EEA United States;
GW Research Ltd.
2017 Phase 3 EUCTR2015-002154-12-NL Australia;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-002154-12-ES Australia;France;Netherlands;Poland;Spain;United Kingdom;United States;
- Phase 3 EUCTR2015-002154-12-PL Australia;Netherlands;Poland;Spain;United Kingdom;United States;
Ganaxolone
Marinus Pharmaceuticals
2020 Phase 2 NCT04285346 United States;
Gold
An Zhen Hospital affiliated to Capital Medical University, Beijing
Beijing Key Laboratory of Fetal Heart Diseases and Maternal-Fetal Medicine
L04AA18
Erasmus MC - Department of Neurology
2012 - EUCTR2010-019519-39-NL Netherlands;
Metformin (generic)
University Hospitals Bristol NHS Foundation Trust
2012 Phase 4 EUCTR2011-001319-30-GB United Kingdom;
Metformin hydrochloride
University Hospitals Bristol NHS Foundation Trust
2012 Phase 4 EUCTR2011-001319-30-GB United Kingdom;
NPC-12G gel
Nobelpharma
2015 Phase 3 NCT02635789 Japan;
2015 Phase 3 NCT02634931 Japan;
Open label RAD001 (only used for post-extension phase)
Novartis Pharmaceuticals
2013 Phase 3 NCT01713946 Argentina;Australia;Belgium;Canada;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Petrolatum
Department of DermatologyGraduate School of Medicine, Osaka University
2009 Phase 2,3 JPRN-UMIN000002844 Japan;
Propranolol
University Hospital, Bordeaux
2015 Phase 2 NCT02104011 France;
RAD001
Cardiff University
2012 Phase 2 EUCTR2011-004854-25-GB United Kingdom;
Children's Hospital Medical Center, Cincinnati
2005 Phase 1/Phase 2 NCT00457964 United States;
Mustafa Sahin
2011 Phase 2 NCT01289912 United States;
NOVARTIS FARMA
2013 Phase 3 EUCTR2011-000860-90-IT Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2011 - EUCTR2010-022583-13-IT Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
2009 - EUCTR2008-002113-48-IT France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2007-006997-27-IT Belgium;Germany;Italy;Netherlands;United Kingdom;
Novartis Farmacéutica S.A
2017 Phase 3 EUCTR2016-002977-37-ES Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Novartis Farmacéutica, S.A
2013 - EUCTR2012-005397-63-ES Spain;
Novartis Farmacéutica, S.A.
2013 Phase 3 EUCTR2011-000860-90-ES Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Novartis Pharma AG
2017 Phase 3 EUCTR2016-002977-37-HU Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002977-37-GB Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002977-37-FR Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002977-37-BE Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2016-002977-37-PL Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Novartis Pharma Services AG
2014 Phase 3;Phase 4 EUCTR2013-003795-13-BE Belgium;Canada;Poland;Russian Federation;United States;
2014 Phase 3 EUCTR2011-000860-90-IE Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-NL Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-HU Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-GR Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-GB Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-DK Argentina;Belgium;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Spain;Taiwan;Turkey;United Kingdom;
2013 Phase 3 EUCTR2011-000860-90-DE Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-BE Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022583-13-CZ Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain;
2011 Phase 3 EUCTR2010-022583-13-BE Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
2011 - EUCTR2010-022583-13-HU Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
2011 - EUCTR2010-022583-13-GR Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
2011 - EUCTR2007-006997-27-BE Belgium;Germany;Italy;Netherlands;United Kingdom;
2010 - EUCTR2008-002113-48-NL France;Germany;Italy;Netherlands;Spain;United Kingdom;
2010 - EUCTR2007-006997-27-NL Australia;Belgium;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;
2010 - EUCTR2007-006997-27-DE Belgium;Germany;Italy;Netherlands;United Kingdom;
2009 Phase 3 EUCTR2008-002113-48-GB Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
2009 Phase 3 EUCTR2008-002113-48-FR France;Germany;Italy;Netherlands;Spain;United Kingdom;
- Phase 3 EUCTR2013-003795-13-PL Belgium;Canada;Poland;Russian Federation;United States;
- Phase 3 EUCTR2010-022583-13-FR Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain;
- Phase 3 EUCTR2008-002113-48-DE Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
RAD001 2,
Novartis Pharma Services AG
- - EUCTR2010-022583-13-DE Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
RAD001 round tablets
Novartis Pharma Services AG
2009 Phase 3 EUCTR2007-006997-27-GB Belgium;Germany;Italy;Netherlands;United Kingdom;
RAPAMUNE 1 mg/ml oral solution
The Children's Memorial Health Institute
- Phase 2;Phase 3 EUCTR2020-003231-19-PL Poland;
Rapamune
Erasmus MC
2011 - EUCTR2010-022655-29-NL Netherlands;
FUNDACIÓ PUIGVERT
2008 - EUCTR2007-005978-30-ES Spain;
Le Bonheur Children's Hospital
2013 Phase 1 NCT01853423 United States;
Rapamune 1 mg/ml solución oral
Fundación Investigación Hospital Ramón y Cajal
2012 - EUCTR2011-006308-12-ES Spain;
Rapamycin
Chinese PLA General Hospital
2015 - ChiCTR-OOB-15006535 China;
Department of Dermatology Graduate School of Medicine, Osaka University
2014 Phase 2,3 JPRN-UMIN000015114 Japan;
2011 Phase 2,3 JPRN-UMIN000006108 Japan;
Department of DermatologyGraduate School of Medicine, Osaka University
2009 Phase 2,3 JPRN-UMIN000002844 Japan;
Dermatology Specialties Limited Partnership
2019 Phase 2/Phase 3 NCT03826628 Australia;Czechia;Hungary;New Zealand;Serbia;Slovakia;Spain;Taiwan;United Kingdom;United States;
The University of Texas Health Science Center, Houston
2012 Phase 2 NCT01526356 Australia;United States;
Rapamycin cream, topical, , w/w
DSLP
2019 Phase 2;Phase 3 EUCTR2019-000752-34-SK Australia;Hungary;New Zealand;Slovakia;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000752-34-HU Australia;Hungary;New Zealand;Slovakia;Spain;United Kingdom;United States;
Dermatology Specialities Limited Partnership (DSLP)
- Phase 2;Phase 3 EUCTR2019-000752-34-CZ Australia;Czech Republic;Hungary;New Zealand;Serbia;Slovakia;Spain;United States;
Rapamycin, sirolimus
Children's Hospital Medical Center, Cincinnati
2002 Phase 2 NCT00457808 United States;
Rapamycin-calcitriol combination
National Taiwan University Hospital
2013 Phase 3 NCT03140449 -
SABRIL 500 mg, granules for oral solution
The Children's Memorial Health Institute
- Phase 2;Phase 3 EUCTR2020-003231-19-PL Poland;
SOC
GW Research Ltd
2021 Phase 3 NCT04485104 United States;
Simvastatin
University of Pennsylvania
2014 Phase 1/Phase 2 NCT02061397 United States;
Sirolimus
Aucta Pharmaceuticals, Inc
2017 Phase 2 NCT03363763 China;United States;
Cardiff University
2005 Phase 2 NCT00490789 United Kingdom;
Darcy Krueger
2021 Phase 2 NCT05104983 United States;
Department of DermatologyGraduate School of Medicine, Osaka University
2013 Phase 1,2 JPRN-UMIN000012420 Japan;
FUNDACIÓ PUIGVERT
2008 - EUCTR2007-005978-30-ES Spain;
Fundacio Puigvert
2008 Phase 4 NCT01217125 -
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
2013 Phase 2 NCT01929642 United States;
West China Hospital, Sichuan University
2020 - ChiCTR2000031984 China;
Sirolimus Oral Product
University of Pennsylvania
2014 Phase 1/Phase 2 NCT02061397 United States;
Skincerity plus sirolimus/rapamycin
The University of Texas Health Science Center, Houston
2009 Phase 1 NCT01031901 United States;
Skinercity plus sirolimus/rapamycin
The University of Texas Health Science Center, Houston
2009 Phase 1 NCT01031901 United States;
TAVT-18 (sirolimus)
Children's Hospital Medical Center, Cincinnati
2020 Phase 1/Phase 2 NCT04595513 United States;
Tacrolimus
Department of DermatologyGraduate School of Medicine, Osaka University
2009 Phase 2,3 JPRN-UMIN000002844 Japan;
Turmeric
NYU Langone Health
2018 - NCT03254680 United States;
Vigabatrin
Martina Bebin
2016 Phase 2 NCT02849457 United States;
University of Pennsylvania
2010 Phase 4 NCT01266291 United States;
Vigabatrin (Sabril)
The Children's Memorial Health Institute
2014 - EUCTR2013-005528-40-NL Belgium;Netherlands;
Vigabatrin (sabril)
Vrije Universiteit Brussel
2014 - EUCTR2013-005528-40-BE Belgium;Netherlands;
Votubia
Erasmus MC - Department of Neurology
2012 - EUCTR2010-019519-39-NL Netherlands;
NOVARTIS PHARMA AG
2019 Phase 3 EUCTR2016-002977-37-IT Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Novartis Farmacéutica S.A
2017 Phase 3 EUCTR2016-002977-37-ES Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Novartis Farmacéutica, S.A
2013 - EUCTR2012-005397-63-ES Spain;
Novartis Pharma AG
2017 Phase 3 EUCTR2016-002977-37-HU Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002977-37-GB Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002977-37-FR Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002977-37-BE Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2016-002977-37-PL Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Novartis Pharma Services AG
2014 Phase 3;Phase 4 EUCTR2013-003795-13-BE Belgium;Canada;Poland;Russian Federation;United States;
2014 Phase 3 EUCTR2011-000860-90-IE Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-NL Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-HU Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-GB Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2011-000860-90-DK Argentina;Belgium;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Spain;Taiwan;Turkey;United Kingdom;
2013 Phase 3 EUCTR2011-000860-90-BE Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2011 Phase 3 EUCTR2010-022583-13-BE Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
- Phase 3 EUCTR2013-003795-13-PL Belgium;Canada;Poland;Russian Federation;United States;